Fig. 3From: Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomasRisk stratification, proposed prognostic biomarkers, and major mechanisms of tumorigenesis in group 4 medulloblastomas (a). Schematic representation of major mechanisms most frequently affected by somatic alterations within group 4 MBs contributing to medulloblastoma development (b). LR, low risk; HR, high riskBack to article page